CClinicalTrials.gg
CompletedNCT01269541MESSUpdated Aug 22, 2017

MESS-study MRSA Eradication Study Skåne

An interventional study of Mupirocin and Rifampin+Clindamycine or Trimehoprimsulfa in Throatcarriers of MRSA, sponsored by Region Skane. Completed at 6 sites in Sweden. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by Region Skane · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

02

Conditions studied

  • Throatcarriers of MRSA
03

In context

Lead sponsor

Region Skane is the lead sponsor of 372 studies on the registry; 113 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion criteria

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    Mupirocin

    Topical treatment

    Drug: Mupirocin · Drug: Rifampin+Clindamycine or Trimehoprimsulfa

  • Active comparator
    Rifampicin+Clindamycine or Trimethoprimsulfa

    Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2

    Drug: Rifampin+Clindamycine or Trimehoprimsulfa

Interventions

  • DrugMupirocin

    Topical in the nose 3 times daily for 5 days

  • DrugRifampin+Clindamycine or Trimehoprimsulfa

    Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

06

What researchers measure

Primary outcomes

  1. Culture for MRSA

    Time frame: after 6 months

07

Study locations

6 sites
  • Helsingborg hospital
    Helsingborg, Skåne, Sweden
  • Kristianstad hospital
    Kristianstad, Skåne, Sweden
  • Infectious department SUS Lund
    Lund, Skåne, Sweden
  • SUS Malmö
    Malmö, Skåne, Sweden
  • Karolinska university hospital
    Stockholm, Sweden
  • Örebro university hospital
    Örebro, Sweden
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01269541
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Jan 4, 2011
Start date
Mar 1, 2011
Primary completion
May 1, 2015
Completion
May 1, 2015
Last update
Aug 22, 2017

Study contacts

Eva Melander, MD PHD
principal investigator · Labmedicin Skåne Malmö

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion